Oragenics (OGEN) Stock Price, News & Analysis

Company Overview

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Key Stats

• Today's Range: $0.32 to $0.40
• 50-Day Range: $0.27 to $0.39
• 52-Week Range: $0.25 to $7.74
• Volume: 1.36 million shs
• Average Volume: 437,024 shs
• Market Capitalization: $4.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed this year?

Oragenics' stock was trading at $6.1382 at the beginning of 2024. Since then, OGEN shares have decreased by 94.2% and is now trading at $0.3552.
View the best growth stocks for 2024 here.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSE:OGEN) released its quarterly earnings results on Monday, August, 16th. The company reported ($1.80) earnings per share for the quarter, topping the consensus estimate of ($2.40) by $0.60.

When did Oragenics' stock split?

Oragenics shares reverse split on the morning of Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), iBio (IBIO), Jaguar Health (JAGX), NIO (NIO), Bionano Genomics (BNGO) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 8/16/2021
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:OGEN
• Previous Symbol: NYSE:OGEN
• CUSIP: N/A
• CIK: 1174940
• Web: www.oragenics.com
• Phone: 813-286-7900
• Fax: 813-286-7904
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($7.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,660,000.00
• Net Margins: N/A
• Pretax Margin: -243,950.00%
• Return on Equity: -2,087.95%
• Return on Assets: -486.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.93
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $40,000.00
• Price / Sales: 108.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 12,213,000
• Free Float: 10,979,000
• Market Cap: $4.34 million
• Optionable: N/A
• Beta: 0.43